scholarly journals Differential expression of the novel oncogene, SALL4, in lymphoma, plasma cell myeloma, and acute lymphoblastic leukemia

2006 ◽  
Vol 19 (12) ◽  
pp. 1585-1592 ◽  
Author(s):  
Wei Cui ◽  
Nikki R Kong ◽  
Yupo Ma ◽  
Hesham M Amin ◽  
Raymond Lai ◽  
...  
Keyword(s):  
Acute Lymphoblastic Leukemia ◽  
Differential Expression ◽  
Plasma Cell ◽  
Lymphoblastic Leukemia ◽  
The Novel ◽  
Plasma Cell Myeloma

scholarly journals Two Rare Cases of Therapy-Related Acute Lymphoblastic Leukemia in Patients With Plasma Cell Myeloma

2019 ◽  
Vol 39 (5) ◽  
pp. 496-498 ◽  
Author(s):  
Hye-Young Lee ◽  
Chan-Jeoung Park ◽  
Ari Ahn ◽  
Min Yung Lee ◽  
Young-Uk Cho ◽  
...  
Keyword(s):  
Acute Lymphoblastic Leukemia ◽  
Plasma Cell ◽  
Lymphoblastic Leukemia ◽  
Plasma Cell Myeloma

scholarly journals B-cell acute lymphoblastic leukemia in an elderly man with plasma cell myeloma and long-term exposure to thalidomide and lenalidomide: a case report and literature review

BMC Cancer ◽  
2019 ◽  
Vol 19 (1) ◽  
Author(s):  
Ryan B. Sinit ◽  
Dick G. Hwang ◽  
Prakash Vishnu ◽  
Jess F. Peterson ◽  
David M. Aboulafia
Keyword(s):  
Acute Lymphoblastic Leukemia ◽  
B Cell ◽  
Plasma Cell ◽  
De Novo ◽  
Lymphoblastic Leukemia ◽  
Second Primary ◽  
Plasma Cell Myeloma ◽  
Sequence Of Events ◽  
Increased Risk ◽  
Cell Acute Lymphoblastic Leukemia

Abstract Background The advent of the immunomodulatory imide drugs (IMiDs) lenalidomide and thalidomide for the treatment of patients with plasma cell myeloma (PCM), has contributed to more than a doubling of the overall survival of these individuals. As a result, PCM patients join survivors of other malignancies such as breast and prostate cancer with a relatively new clinical problem – second primary malignancies (SPMs) – many of which are a result of the treatment of the initial cancer. PCM patients have a statistically significant increased risk for acute myeloid leukemia (AML) and Kaposi sarcoma. IMiD treatment has also been associated with an increased risk of myelodysplastic syndrome (MDS), AML, and squamous cell carcinoma of the skin. However, within these overlapping groups, acute lymphoblastic leukemia (ALL) is much less common. Case presentation Herein, we describe an elderly man with PCM and a 14-year cumulative history of IMiD therapy who developed persistent pancytopenia and was diagnosed with B-cell acute lymphoblastic leukemia (B-ALL). He joins a group of 17 other patients documented in the literature who have followed a similar sequence of events starting with worsening cytopenias while on IMiD maintenance for PCM. These PCM patients were diagnosed with B-ALL after a median time of 36 months after starting IMiD therapy and at a median age of 61.5 years old. Conclusions PCM patients with subsequent B-ALL have a poorer prognosis than their de novo B-ALL counterparts, however, the very low prevalence rate of subsequent B-ALL and high efficacy of IMiD maintenance therapy in PCM should not alter physicians’ current practice. Instead, there should be a low threshold for bone marrow biopsy for unexplained cytopenias.

scholarly journals Emerging Pharmacotherapies for Adult Patients with Acute Lymphoblastic Leukemia

2012 ◽  
Vol 6 ◽  
pp. CMO.S7262 ◽  
Author(s):  
Lydia Lee ◽  
Adele K. Fielding
Keyword(s):  
Acute Lymphoblastic Leukemia ◽  
Lymphoblastic Leukemia ◽  
Sustained Remission ◽  
The Novel ◽  
Durable Response ◽  
Treatment Regimes ◽  
The Face ◽  
Pediatric All ◽  
Relapsed Disease ◽  
Failure Of Induction

Acute lymphoblastic leukemia (ALL) treatment regimes are amongst the longest, most intensive and complex used in hemato-oncology. Despite this, while treatment of pediatric ALL is a success story, we are far from being able to ensure a durable response in adult ALL. This is not due to failure of induction therapy as a complete remission (CR) is achieved in over 90% of patients. However the challenge remains in ensuring a sustained remission. Furthermore in the face of relapsed disease, salvage therapies currently offer a poor chance of a good outcome. This article reviews the novel agents which show the most promise in the treatment of adult ALL.

scholarly journals Cytotoxic activity of the novel Akt inhibitor, MK-2206, in T-cell acute lymphoblastic leukemia

Leukemia ◽  
2012 ◽  
Vol 26 (11) ◽  
pp. 2336-2342 ◽  
Author(s):  
C Simioni ◽  
L M Neri ◽  
G Tabellini ◽  
F Ricci ◽  
D Bressanin ◽  
...  
Keyword(s):  
Acute Lymphoblastic Leukemia ◽  
T Cell ◽  
Cytotoxic Activity ◽  
Lymphoblastic Leukemia ◽  
The Novel ◽  
Akt Inhibitor ◽  
Cell Acute Lymphoblastic Leukemia

scholarly journals Marked Variability in Reported Minimal Residual Disease Lower Level of Detection of 4 Hematolymphoid Neoplasms: A Survey of Participants in the College of American Pathologists Flow Cytometry Proficiency Testing Program

2015 ◽  
Vol 139 (10) ◽  
pp. 1276-1280 ◽  
Author(s):  
Michael Keeney ◽  
Jaimie G. Halley ◽  
Daniel D. Rhoads ◽  
M. Qasim Ansari ◽  
Steven J. Kussick ◽  
...  
Keyword(s):  
Flow Cytometry ◽  
Chronic Lymphocytic Leukemia ◽  
Minimal Residual Disease ◽  
Plasma Cell ◽  
Myeloid Leukemia ◽  
Residual Disease ◽  
Lymphoblastic Leukemia ◽  
Lymphocytic Leukemia ◽  
Plasma Cell Myeloma ◽  
Minimal Residual

Context Flow cytometry is often applied to minimal residual disease (MRD) testing in hematolymphoid neoplasia. Because flow-based MRD tests are developed in the laboratory, testing methodologies and lower levels of detection (LODs) are laboratory dependent. Objectives To broadly survey flow cytometry laboratories about MRD testing in laboratories, if performed, including indications and reported LODs. Design Voluntary supplemental questions were sent to the 549 laboratories participating in the College of American Pathologists (CAP) FL3-A Survey (Flow Cytometry—Immunophenotypic Characterization of Leukemia/Lymphoma) in the spring of 2014. Results A total of 500 laboratories (91%) responded to the supplemental questions as part of the FL3-A Survey by April 2014; of those 500 laboratories, 167 (33%) currently perform MRD for lymphoblastic leukemia, 118 (24%) for myeloid leukemia, 99 (20%) for chronic lymphocytic leukemia, and 91 (18%) for plasma cell myeloma. Other indications include non-Hodgkin lymphoma, hairy cell leukemia, neuroblastoma, and myelodysplastic syndrome. Most responding laboratories that perform MRD for lymphoblastic leukemia reported an LOD of 0.01%. For myeloid leukemia, chronic lymphocytic leukemia, and plasma cell myeloma, most laboratories indicated an LOD of 0.1%. Less than 3% (15 of 500) of laboratories reported LODs of 0.001% for one or more MRD assays performed. Conclusions There is major heterogeneity in the reported LODs of MRD testing performed by laboratories subscribing to the CAP FL3-A Survey. To address that heterogeneity, changes to the Flow Cytometry Checklist for the CAP Laboratory Accreditation Program are suggested that will include new requirements that each laboratory (1) document how an MRD assay's LOD is measured, and (2) include the LOD or lower limit of enumeration for flow-based MRD assays in the final diagnostic report.

Sign in / Sign up

Export Citation Format

Share Document